Unlikely to be anything in there we've not already been made aware of.
Unless the analysts have medical expertise in dendritic cell therapy and immunology then I imagine it will mostly be marker based info, and would hazard a guess that they'd say it's a high risk stock (duh!). ; )
I think the benefit will be for US investors who have no idea who Prima are. This will serve as an introduction for them to further their own research on.
- Forums
- ASX - By Stock
- IMM
- swot analysis review
swot analysis review , page-2
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16911 | 40.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 154170 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16911 | 0.400 |
6 | 104590 | 0.395 |
6 | 65668 | 0.390 |
6 | 98699 | 0.385 |
10 | 114110 | 0.380 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 154170 | 1 |
0.410 | 259670 | 7 |
0.415 | 187366 | 8 |
0.420 | 484307 | 7 |
0.425 | 69000 | 3 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |